<code id='71BCC9C0CA'></code><style id='71BCC9C0CA'></style>
    • <acronym id='71BCC9C0CA'></acronym>
      <center id='71BCC9C0CA'><center id='71BCC9C0CA'><tfoot id='71BCC9C0CA'></tfoot></center><abbr id='71BCC9C0CA'><dir id='71BCC9C0CA'><tfoot id='71BCC9C0CA'></tfoot><noframes id='71BCC9C0CA'>

    • <optgroup id='71BCC9C0CA'><strike id='71BCC9C0CA'><sup id='71BCC9C0CA'></sup></strike><code id='71BCC9C0CA'></code></optgroup>
        1. <b id='71BCC9C0CA'><label id='71BCC9C0CA'><select id='71BCC9C0CA'><dt id='71BCC9C0CA'><span id='71BCC9C0CA'></span></dt></select></label></b><u id='71BCC9C0CA'></u>
          <i id='71BCC9C0CA'><strike id='71BCC9C0CA'><tt id='71BCC9C0CA'><pre id='71BCC9C0CA'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:9329
          A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT
          Christine Kao/STAT

          Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

          The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

          advertisement

          Here are three CRISPR developments we’re watching in 2024:

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          RSV vaccines may be linked to small increased risk of developing GBS
          RSV vaccines may be linked to small increased risk of developing GBS

          CourtesyPfizerThenewvaccinesthatprotectolderadultsagainstrespiratorysyncytialvirus,orRSV,maybelinked

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne